Recently, the members of Association of Southeast Asian Nations (ASEAN) attempted to improve product registration efficiency and marketing approval for pharmaceutical products. The ASEAN harmonization regime hopes to improve the standard of the Food and Drug Administrations’ (FDAs) regulatory reviews in ASEAN countries. Despite these efforts, however, the lingering obstacle of a lack of intellectual property understanding continues to leave pharmaceutical companies with difficulties when dealing with product registration in several ASEAN FDAs.